LPCN 1021 is a new twice-a-day oral testosterone replacement therapy intended to treat men with a deficiency or absence of endogenous testosterone.
The FDA cited deficiencies in the dosing algorithm for the drug’s label as the reason for denial.
Salt Lake City-based Lipocine plans to meet with the FDA to further address the drug’s issues and work toward approval.
More articles on the drug market:
FDA approves drug for treatment of 6 types of hepatitis C
Roche’s new MS drug to hit market sooner than expected
Novartis partners with Xencor to develop bispecific antibodies
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
